Your search for bevacizumab returned 17 results

The systemic safety of bevacizumab appears to be similar to that of ranibizumab as intravitreal therapy for neovascular age-related macular degeneration (AMD).

Adjuvant bevacizumab increases overall survival in cervical cancer and improves progression-free survival in glioblastoma.

No evidence of infection, inflammation when bevacizumab is stored at 4 Celsius for a week

Findings show benefits compared with FOLFIRI for patients with untreated metastatic disease.

Both linked to improvements in visual acuity; only triamcinolone tied to sustained improvement in CMT

For patients with diabetic macular edema (DME), visual acuity (VA) improves over two years with treatment with different anti-vascular endothelial growth factor (VEGF) agents, according to a study published online in Ophthalmology.

By switching preferred therapy for macular degeneration, Medicare can realize substantial cost savings.

Dose-dense weekly paclitaxel does not improve progression-free survival in ovarian cancer, according to a study published in the New England Journal of Medicine.

An experimental vaccine and a drug already on the market each may help slow down advanced ovarian cancer, two new studies suggest.

For women with platinum-resistant ovarian cancer, the addition of Avastin (bevacizumab) to chemotherapy is associated with improved progression-free survival.